

SOMATONORM 4 IU ▼

PRESCRIBING INFORMATION

PRESENTATION

A vial of sterile lyophilised powder of somatrem corresponding to 4 IU of human somatotropin (also containing aminoacetic acid and sodium phosphate as stabilisers) and supplied with a 2 ml ampoule of water for injections for use in the reconstitution of the injection.

USES

The treatment of short stature caused by decreased or absent secretion of pituitary growth hormone. The diagnosis should be verified by appropriate investigations of pituitary function by a specialist medical practitioner.

DOSE AND ADMINISTRATION

Route of administration:

By intramuscular injection.

Recommended dosage:

The dosage should be calculated according to the patient's body weight. Generally a dose of 0.5 IU/kg body weight per week is recommended. This weekly dose should be divided into 2 or 3 intramuscular injections.

PREPARATION OF SOLUTION

The solution is prepared by adding 2 ml of water for injections to the lyophilised substance in the vial. Gently dissolve the drug with a slow swirling motion. Do not shake vigorously as this may cause denaturation of the active ingredient.

CONTRA-INDICATIONS, WARNINGS, ETC.

Only patients with unfused epiphyses should be treated. Diabetes mellitus.

Precautions:

Patients treated with Somatonorm should be regularly assessed by a specialist in child growth. This assessment should include determination of growth response and endocrinological status, as relative deficiencies of other pituitary hormones may be exposed or exacerbated by an adequate growth response.

Overdosage:

Acute overdosage is unlikely and does not represent a hazard to the patient. The consequences of long term administration of doses above the normal therapeutic range are unknown.

Side-effects:

Clinical experience with Somatonorm is limited and recipients may develop antibody to growth hormone and E. coli protein. However, as with pituitary derived hormone, only in very rare instances has growth retardation occurred. No other adverse reactions have been noted.

PHARMACEUTICAL PRECAUTIONS

Store at 2-8°C. Reconstituted Somatonorm may be stored in the refrigerator for 24 hours before use.

LEGAL CATEGORY

POM.

PACKAGE QUANTITIES

Combined package containing one vial of somatrem 4 IU and one ampoule of 2 ml water for injections.

FURTHER INFORMATION

Somatonorm is produced using recombinant DNA technology. Somatrem is the British Approved Name for methionyl human somatotropin.

PRODUCT LICENCE NUMBER

0022/0060 P.A. 187/28/1

N.H.S. Price £ 28

For the first time
in the history of medicine
we can supply growth hormone
to every child
suffering from short stature
due to growth hormone deficiency.

Somatonorm[®]

Recombinant Growth Hormone somatrem



Minimises the risk of transmissible disease
through recombinant DNA technology.

Extremely low levels of ECP
achieved by leading purification technology.

KabiVitrum Ltd • KabiVitrum House • Riverside Way • Uxbridge •
Middlesex UB8 2YF • Tel. (0895) 51144

KabiVitrum (Eire) • Cahill May Roberts Ltd • PO Box 1090 •
Chapelizod • Dublin 20 • Tel. Dublin 267111

The intensive research and development of Somatonorm reflects KabiVitrum's continuing commitment in the field of growth and growth factors.



THE PROVEN ANSWER TO THE PRESENT DAY QUESTION...

NUTRITION OF
LOW BIRTHWEIGHT INFANTS


NUTRITIONAL NEEDS	-HIGH
BODY NUTRIENT STORES	-LOW
DIGESTIVE SYSTEM	-IMMATURE
METABOLIC SYSTEM	-IMMATURE
EXCRETORY SYSTEM	-IMMATURE
STOMACH CAPACITY	-LOW

REQUIREMENTS

EASILY DIGESTED WELL TOLERATED FORMULA. MEET HIGH NUTRIENT REQUIREMENT. ADAPTED TO MEET SPECIAL NEEDS. APPROPRIATE FOR AGA AND SGA BABIES. READY TO FEED. PURE AND STERILE TO PROTECT IMMATURE DIGESTIVE SYSTEM. SCREENED AGAINST HERBICIDES, PESTICIDES AND LEAD.

THE ANSWER IS:

PRE-APTAMIL (MEB) BY MILLUPA. PROVEN BY OVER 10 YEARS SUCCESSFUL USE IN EUROPE AND BY UK CLINICAL TRIAL!



Pre-Aptamil (MEB)

For further information contact Janet Souster BSc at Milupa Limited, Milupa House, Hercules Road, Hillingdon, Uxbridge, Middlesex UB10 9NA. Telephone (0895) 59851

1. Brooke, O. G., Wood, C., Barley, J. Arch. Dis. Child 1982, 57, 898-904.

European Journal of **Pediatrics**

Incorporating
ACTA PAEDIATRICA BELGICA

Volume 145 Number 1-2 April 1986

The pioneers of pediatric medicine 1

Editorial

Burgio: Sir Garrod's 'Inborn Errors of Metabolism' and 'Chemical Individuality' 2

Annotation

Laron and Baumann: Growth hormone releasing hormone 6

Original investigations

Triadou et al.: Neocytopheresis in thalassaemia major 10

Janka-Schaub et al.: Intermediate-dose methotrexate in acute lymphocytic leukaemia 14

Grønn et al.: C-reactive protein in infections of the immunosuppressed child 18

Ishii et al.: Protein phosphorylation of neutrophils in chronic granulomatous disease 22

Kruse and Kracht: Serum osteocalcin as an index of altered bone metabolism 27

Stöß et al.: Heterogeneity of osteogenesis imperfecta 34

Rosenberg and Löhr: A new hereditary bone dysplasia 40

Clayton et al.: Mitochondrial phosphoenolpyruvate carboxylase deficiency 46

De Luca et al.: Prenatal exclusion of purine nucleoside phosphorylase deficiency 51

Tazawa et al.: Lipoprotein-X and gammaglutamyltranspeptidase in biliary atresia 54

Den Ouden et al.: Scarring of the hands from venipunctures in babies 58

Mulder and Zanen: *Listeria monocytogenes* neonatal meningitis 60

Iwai et al.: Iron status in low birth weight infants on breast and formula feeding 63

Van Acker et al.: Haemorrhagic shock and encephalopathy 66

Lanes et al.: Pituitary-thyroidal axis in newborns undergoing exchange transfusion 70

de Beaufort et al.: Overnight metabolic profiles in very young diabetic children 73

De Luca et al.: Thyroid function tests and carbamazepine in hypothyroid children 77

Schöni et al.: Dopamine-beta-hydroxylase in patients with cystic fibrosis 80

Larizza et al.: Difficult hGH treatment in type III glycogen storage disease 84

Fennell et al.: Statural growth following kidney transplantation 86

Variend and Howat: Renal glomerular size in CHD and in sudden infant death 90

Deutsch et al.: Epstein-Barr virus DNA in fulminant hepatic failure 94

Mayumi et al.: Immunoglobulin M deficiency and disseminated molluscum contagiosum 99

Furukawa et al.: Polyclonal B cell activation in mucocutaneous lymph node syndrome 104

Koletzko et al.: Fatty acid composition of plasma lipids in protein-energy malnutrition 109

Trowitsch et al.: Severe pulmonary arterial stenoses in Conradi-Hünermann disease 116

Sumer et al.: Severe congenital factor X deficiency with intracranial haemorrhage 119

Tsukahara et al.: Ataxia telangiectasia, skin pigmentation and early death 121

Lauffer et al.: Anuria in a premature infant due to ureteropelvic fungal bezoar 125

Short communications

Eiholzer et al.: Recovery from post-traumatic anterior pituitary insufficiency 128

Leiberman et al.: Low grade mucoepidermoid tumour of the bronchus 130

Zamboni et al.: Parathyroid hormone, calcitonin and vitamin D metabolites in beta-thalassaemia major 133

Wanders et al.: Prenatal test for Zellweger syndrome 136

Ashkenazi et al.: Effect of splenectomy on destructive bone changes in Gaucher disease 138

Case reports

Wales et al.: Partial trisomy 11 - bronze baby - biliary hypoplasia - Wiedemann-Beckwith syndrome 141

Wit et al.: Thyroid-stimulating immunoglobulins and thyroid function tests in neonatal thyrotoxicosis 143

Hadjilambris: True precocious puberty and CNS-hamartoma 148

Shuper et al.: Dubowitz Syndrome in the neonatal period 151

Muis et al.: Aase syndrome 153

Letters to the editors 157

Indexed in *Current Contents*

Subscription information: Volume 145 (6 issues) will appear in 1986. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: Approx. US \$ 335.00 including carriage charges. Subscriptions are entered with prepayment only. Orders should be addressed to: Springer-Verlag New York Inc., Service Center Secaucus, 44 Hartz Way, Secaucus, NJ 07094, USA, Tel. (201) 348-4033, Telex 023 125 994.

All other countries: Annual subscription rate: DM 896.00 plus carriage charges. Volume price: DM 896.00, single issue price: DM 179.20 plus carriage charges. Airmail delivery on request only. Carriage charges for S.A.L. (Surface Airmail Lifted) to Japan, India, Australia and New Zealand are available on request. Orders can either be placed with your bookdealer or sent directly to: Springer-Verlag, Heidelberger Platz 3, D-1000 Berlin 33, Tel. (0)30/8207-1, Telex 183319.



Springer International

International coverage of the most important developments in pediatric medicine

PEDIATRIC RESEARCH

An International Journal of Clinical, Laboratory, and Developmental Investigation

Editor-in-Chief: Delbert A. Fisher, MD

Every month, **Pediatric Research** puts you in touch with leading authorities in pediatric pulmonology, endocrinology and metabolism, gastroenterology, and nutrition. You'll read about significant new clinical and laboratory results, as selected and reported by an international array of distinguished contributors and editors.

Abstracts of major society meetings worldwide and occasional supplements on specific issues in pediatric health are also part of the package, but the hallmark of **Pediatric Research** is *research*, and lots of it. Each issue contains some 15 original articles — 4 to 6 pages each — on late-breaking investigations into the most difficult problems of childhood disease.

Cystic fibrosis, hypopituitarism, sudden infant death syndrome, protein intolerance, metabolic disorders, and sickle cell anemia are just a few of the subjects covered in recent issues. As advances are made in the understanding and management of these and other baffling childhood disorders, **Pediatric Research** will continue to be there with timely, accurate, and useful reports from leaders in the field. **Monthly**

Personal: \$90/yr Institutions: \$115/yr
In-training: \$70/yr (add \$15.00 outside the US)



FOR FASTEST SERVICE, call 1-800-638-6423 FREE from anywhere in the US except AK and HI. MD residents, call 528-4105 collect.



P.O. Box 1496 Baltimore, Maryland 21203
266 Fulham Road London SW10 9EL England



PEDIATRIC RESEARCH An International Journal of Clinical, Laboratory, and Developmental Investigation

Research you can't afford to miss... and an offer you can't afford to pass up

Avoid planned rate increases and ensure uninterrupted service by subscribing to **PEDIATRIC RESEARCH** for up to 3 years at current rates.

- New subscription Renewal
 3 yrs 2 yrs 1 yr
 Personal: \$90/yr **Institutions: \$115/yr**
 In-training: \$70/yr
(add \$15.00 outside the US)
 check enclosed bill me
 VISA MasterCard American Express

card # _____ exp. _____

signature/P.O. # _____

Williams & Wilkins

MD residents, please add 5% sales tax. Subscriptions outside the US must be prepaid, in US dollars only. *Residents, fellows, interns, and students:* when applying for the in-training rate, which is limited to three years, please include institution name and training status. Rates valid through October 31, 1986.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to countries outside the US may take up to 16 weeks. Airmail rates available upon request.

Name _____

Address _____

City/State/Zip _____

P.O. Box 1496 Baltimore, Maryland 21203

266 Fulham Road London SW10 9EL England

printed in USA




PDRAD 94454 86

Monatsschrift Kinder- heilkunde

Organ der
Deutschen Gesellschaft
für Kinderheilkunde

134. Band
Heft 4
April 1986

Springer-Verlag
Berlin Heidelberg New York Tokyo

	Thema des Monats	This Month's Topic	
	Immuntherapie bei Viruserkrankungen	Immunotherapy in Viral Diseases	171
H. Schulte-Wissermann, O. Schofer	Immuntherapie bei Viruserkrankungen	Immunotherapy in Viral Diseases	172
	Pädiatrie aktuell	Trends in Paediatrics	182
	Was hat das Kind? Trainingsprogramm für die Weiterbildung zum Kinderarzt	What's Wrong with the Child? Program for Continuing Education of Paediatricians	183
	Aus Klinik und Forschung Originalien	Clinic and Research Originals	
H. H. Kramer, B. Hendrixx, H. J. Trampisch, M. Krüger	Elterngroße und kindliche Größenentwicklung	Parental Height and Children's Growth Development	184
A. Hussein, H. von der Hardt, W. Müller, S. M. Schell	Intravenöse Infusion von Reproterol (ein Beta-2-Mimetikum) in der Therapie des schweren Asthma-Anfalls im Kindesalter	Intravenous Infusion of Reproterol (a Beta-2-Adrenergic Agent) in the Treatment of Acute Severe Asthma in Children	192
K. E. Bonzel, O. Mehls, D. E. Müller-Wiefel, L. Diekmann, R. Wartha, H. Ruder, W. Rascher, K. Schärer	Kontinuierliche ambulante Peritonealdialyse (CAPD) bei Kindern und Jugendlichen	Continuous Ambulatory Peritoneal Dialysis (CAPD) in Children and Adolescents	197
	Der interessante Fall	Interesting Cases	
L. Gortner, F. Pohlandt	Austauschtransfusion über einen peripheren arterio-venösen Gefäßzugang bei Frühgeborenen	Peripheral Arteries and Veins for Exchange Transfusion in Very Low Birthweight Infants	205
H. Steigenberger	Transitorischer Diabetes mellitus des Neugeborenen	Transient Diabetes Mellitus in the Newborn	207
W. Beck, P. Stubbe	Verlaufsbeobachtung eines kindlichen Prolaktinproduzierenden Hypophysentumors	Follow-up Study of a Prolactin-Producing Pituitary Tumor in an Adolescent	209
Th. Bömelburg, C. Ehringhaus, R. Ziegler, H.-J. von Lengerke, C. Timm	Hüftkopfnekrose bei Sichelzellanämie	Caput Femoris Necrosis in Sickle Cell Anemia	212
	Wußten Sie schon? <i>Neues aus Therapie und Prophylaxe</i>	Do You Know? <i>New Developments in Therapy and Prophylaxis</i>	
H.-J. Radü	Das Diagnoseproblem: Hörstörungen im Kindesalter	Hearing Loss as a Diagnostic Problem in Children	216
	Auflösung und Kommentar des Trainingsprogramms für die Weiterbildung zum Kinderarzt	Solution and Commentary in the Program for Continuing Education of Paediatricians	219
	Neue Bücher	New Books	220
	Tagesgeschichte, Personalia	News of the Day, Personal News	221
	Tagungskalender	Forthcoming Meetings	221
	Für die Dokumentation	Documentation	A 64



Royal Postgraduate Medical School

(University of London)

Neonatal Infection: Rapid Diagnosis and New Treatments

17-19 November 1986

**A 3-day course suitable for
Paediatricians and Microbiologists**

Topics include: Neutrophil Turnover in Newborns
 C-Reactive Protein
 Bacterial Antigens and Antibody
 Detection
 Meningitis
 Shunt Infections
 Granulocyte Transfusion
 Bacteria, Prostaglandins and
 Preterm Labour
 Immunodeficiency: Congenital and
 Acquired
 Monitoring Antimicrobial Therapy
 Antiviral Chemotherapy
 Chlamydia and Mycoplasma
 Systemic Candidiasis

Course fee: £120 including catering

Application forms School Office
 from: Royal Postgraduate Medical School
 Hammersmith Hospital
 Du Cane Road
 London W12 0HS

Telephone: 01 740 3117/8



This publication is available in microform.

University Microfilms

International reproduces this
publication in microform:
microfiche and 16mm or
35mm film. For information
about this publication or any
of the more than 13,000 titles

we offer, complete and mail the coupon to: University
Microfilms International, 300 N. Zeeb Road, Ann Arbor,
MI 48106. Call us toll-free for an immediate response:
800-521-3044. Or call collect in Michigan, Alaska and
Hawaii: 313-761-4700.

Please send information about these titles:

Name _____

Company/Institution _____

Address _____

City _____

State _____ Zip _____

Phone () _____

University
Microfilms
International

International Medical Course

Cancer in children

31 May-6 June 1987 in London

This course will focus on relevant recent laboratory research and on controversial areas in clinical practice. A number of tumours listed below, however, will be discussed in depth.

The Director of Studies will be **Professor T J McElwain**, Department of Medicine, Institute of Cancer Research, University of London and **Dr J Pritchard**, Senior Lecturer in Paediatric Oncology, Institute of Child Health, University of London.

The following topics will be discussed:

bone marrow transplantation, diagnostic imaging, symptom control, cytotoxic drug development, molecular biology.

special emphasis will be given to the following tumours:

rhabdomyosarcoma, leukaemia and lymphoma, neuroblastoma, germ cell tumours.

The course is intended for paediatric oncologists, paediatricians and medical oncologists with several years' experience of the clinical management of cancer in children. It is expected that the format of the seminar with the accent on controversy will create an atmosphere of lively debate rather than didacticism and that practising paediatric oncologists and their senior trainees will be attracted to this approach. Less experienced applicants will be considered for late places.




There are vacancies for 35 participants.

Fee £600 (residential) £400 (non-residential).

The seminar sessions will take place at the Eastman Dental Hospital lecture rooms. Resident participants will be accommodated in a nearby hotel. The seminar will disperse after breakfast on Saturday 6 June.

Further information and application forms are available from British Council
Representatives overseas or from Courses Department, The British Council,
65 Davies Street, London W1Y 2AA.

The
British
Council



Pure
innovation
revealed

The range of human insulins from
Nordisk and Wellcome



Full prescribing information available on request from either:-
 Nordisk-UK
 Highview House
 Tattenham Crescent
 Epsom [KT18 5Q]
 Tel. No: Burch Heath (07373) 60621
 The Wellcome Foundation Ltd.
 Crewe Hall
 Crewe
 Cheshire CW1 1UB
 Tel. No: Crewe (0270) 583151

- **Human INSULATARD**
 (Isophane Insulin Injection [NPH], highly purified human insulin [emp])
- **Human VELOSULIN**
 (Neutral Insulin Injection, highly purified human insulin [emp])
- **Human MIXTARD 30/70**
 (Neutral suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection [NPH] - human insulin [emp])
- **Human INTARD 50/50**
 (Neutral suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH] - human insulin [emp])

HUMAN INTARD 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection and 50% Isophane Insulin Injection [NPH]). HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INTARD 50/50 are manufactured from highly purified human insulin (emp). PRESENTATION HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INTARD 50/50 are available in 10ml vials containing 100iu/ml. To provide sensory identification the metal sealing rings of the vial have tactile marks and the vials are also fitted with colour coded tamper-proof caps. USES Treatment of Insulin Dependent Diabetics. Human Velosulin is particularly suitable in the treatment of diabetic coma and precoma. DOSAGE AND ADMINISTRATION Dosage to be determined by the physician, according to the needs of the patient. Avoid accidental intra-vascular injection. CONTRA-INDICATIONS AND WARNINGS Insulin is contra-indicated in hypoglycaemia. In the event of overdosage, glucose should be given either orally or intravenously. Glucagon may also be administered. Human Insulatard, Human Mixtard 30/70, Human Initard 50/50, should not be given intravenously or intravascularly. Treatment with cortico-steroids, oral contraceptives or thyroid hormones may lead to an increase in dosage requirements. Beta-blockers may affect insulin requirements and mask hypoglycaemia. U100 insulin must only be used in U100 syringes. PHARMACEUTICAL PRECAUTION Store at 2 to 8 degrees C, protected from sunlight. Do not freeze. LEGAL CATEGORY P BASIC NHS PRICE HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INTARD 50/50: 10 ml vial £6.95. PRODUCT LICENCE NUMBERS Human Velosulin 3132/0031 and 0003/0211. Human Insulatard 3132/0034 and 0003/0212. Human Mixtard 30/70 3132/0037 and 0003/0213. Human Initard 50/50 3132/0040 and 0003/0214.